IFRX - InflaRx N.V. - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IFRX is currently covered by 3 analysts with an average price target of $5.14. This is a potential upside of $4.25 (477.53%) from yesterday's end of day stock price of $0.89.

InflaRx N.V.'s activity chart (see below) currently has 59 price targets and 58 ratings on display. The stock rating distribution of IFRX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50.48% with an average time for these price targets to be met of 178 days.

Highest price target for IFRX is $10, Lowest price target is $8, average price target is $9.33.

Most recent stock forecast was given by STEVEN SEEDHOUSE from CANTOR FITZGERALD on 29-Apr-2025. First documented stock forecast 04-Dec-2017.

Currently out of the existing stock ratings of IFRX, 16 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$8.15 (440.54%)

3 months 22 days ago
(29-Apr-2025)

1/14 (7.14%)

$8.55 (589.66%)

253

Buy

$10

$8.15 (440.54%)

$8

4 months 25 days ago
(26-Mar-2025)

1/5 (20%)

$8.76 (706.45%)

271

Buy

$8

$6.15 (332.43%)

$8

4 months 30 days ago
(21-Mar-2025)

2/20 (10%)

$6.72 (525.00%)

52

Sell

$2

$2.8

3 years 3 months 7 days ago
(13-May-2022)

4/4 (100%)

$0.54 (36.99%)

113

Buy

$4

$2.15 (116.22%)

$6

3 years 3 months 8 days ago
(12-May-2022)

6/7 (85.71%)

$2.54 (173.97%)

215

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IFRX (InflaRx N.V.) average time for price targets to be met?

On average it took 178 days on average for the stock forecasts to be realized with a an average price target met ratio 50.48

Which analyst has the current highest performing score on IFRX (InflaRx N.V.) with a proven track record?

TIAGO FAUTH

Which analyst has the current lower performing score on IFRX (InflaRx N.V.) with a proven track record?

YATIN SUNEJA

Which analyst has the most public recommendations on IFRX (InflaRx N.V.)?

Tiago Fauth works at WELLS FARGO and has 5 price targets and 3 ratings on IFRX

Which analyst is the currently most bullish on IFRX (InflaRx N.V.)?

Yatin Suneja with highest potential upside - $8.15

Which analyst is the currently most reserved on IFRX (InflaRx N.V.)?

Tiago Fauth with lowest potential downside - -$0

InflaRx N.V. in the News

InflaRx reports Q2 results

* InflaRx press release [https://seekingalpha.com/pr/20192936-inflarx-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IFRX [https://seekingalpha.com/symbol/IFRX]): Q2 For the six months ended June 30, 2025, we realized €39 thousand in revenues from sales of GOHIBIC (vilobelimab).  * We incurred a net loss of €23.0 million, or €0.35 per ordinary share, during the six months ended June 30, 2025, compared to €23.5 million, or €0.40 per...

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiationInflaRx working diligently toward unblinding of stopped Phase 3...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?